Braveheart Bio, Inc. BRVE
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -27.82%
- 1 year
- -27.82%
- Open
- 21.29
- Prev close
- 21.19
- Mkt cap
- 1.94B
- Vol
- 533.67K
- Avg vol
- 479.98K
- EPS
- -6.08
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 20.75
- High
- 21.77
- Forward P/E
- -10.74
- Beta
- 0.00
- Short ratio
- 8.11
- Inst. own
- 28.16%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Dec 8, 2026
- 50-d avg
- 23.64
- 200-d avg
- 24.28
- 1y target
- 45.25
5D chart
Signals (151)
| Name | Time | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 30, 2:35 PM | 1 day ago |
| SMA: Bearish | Oct 30, 2:25 PM | 1 day ago |
| SMA: Bearish | Oct 30, 2:10 PM | 1 day ago |
| MACD: Buy Signal | Oct 30, 1:45 PM | 1 day ago |
| SMA: Bullish | Oct 30, 1:40 PM | 1 day ago |
| SMA: Bearish | Oct 30, 1:10 PM | 1 day ago |
| SMA: Bullish | Oct 30, 1:05 PM | 1 day ago |
| SMA: Bearish | Oct 30, 12:25 PM | 1 day ago |
| SMA: Bearish | Oct 30, 12:20 PM | 1 day ago |
| SMA: Bullish | Oct 30, 12:10 PM | 1 day ago |
| SMA: Bearish | Oct 30, 12:05 PM | 1 day ago |
| MACD: Sell Signal | Oct 30, 12:05 PM | 1 day ago |
| SMA: Bullish | Oct 30, 12:00 PM | 1 day ago |
| MACD: Buy Signal | Oct 30, 12:00 PM | 1 day ago |
| SMA: Bearish | Oct 30, 11:50 AM | 1 day ago |
| MACD: Sell Signal | Oct 30, 11:50 AM | 1 day ago |
| SMA: Bullish | Oct 30, 11:45 AM | 1 day ago |
| MACD: Buy Signal | Oct 30, 11:45 AM | 1 day ago |
| MACD: Sell Signal | Oct 30, 11:40 AM | 1 day ago |
| SMA: Bearish | Oct 30, 11:25 AM | 1 day ago |
| SMA: Bullish | Oct 30, 10:40 AM | 1 day ago |
| SMA: Bearish | Oct 30, 10:35 AM | 1 day ago |
| SMA: Bullish | Oct 30, 10:25 AM | 1 day ago |
| SMA: Bullish | Oct 30, 10:25 AM | 1 day ago |
| MACD: Buy Signal | Oct 30, 10:25 AM | 1 day ago |
| SMA: Bearish | Oct 30, 10:15 AM | 1 day ago |
| SMA: Bullish | Oct 30, 10:10 AM | 1 day ago |
| MACD: Sell Signal | Oct 30, 10:05 AM | 1 day ago |
| SMA: Bearish | Oct 30, 10:00 AM | 1 day ago |
| SMA: Bearish | Oct 30, 10:00 AM | 1 day ago |
| SMA: Bullish | Oct 30, 9:55 AM | 1 day ago |
| SMA: Bullish | Oct 30, 9:55 AM | 1 day ago |
| MACD: Buy Signal | Oct 30, 9:55 AM | 1 day ago |
| SMA: Bearish | Oct 30, 9:40 AM | 1 day ago |
| SMA: Bearish | Oct 30, 9:40 AM | 1 day ago |
| MACD: Sell Signal | Oct 30, 9:40 AM | 1 day ago |
| SMA: Bullish | Oct 30, 9:35 AM | 1 day ago |
| SMA: Bullish | Oct 30, 9:35 AM | 1 day ago |
| MACD: Buy Signal | Oct 30, 9:35 AM | 1 day ago |
| MACD: Sell Signal | Oct 30, 9:30 AM | 1 day ago |
| SMA: Bearish | Oct 29, 3:55 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:55 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:40 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:35 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:30 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:15 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:10 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:10 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 3:10 PM | 2 days ago |
| RSI: Oversold | Oct 29, 2:30 PM | 2 days ago |
| SMA: Bearish | Oct 29, 2:20 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 2:20 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:45 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:35 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:35 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:30 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:30 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:20 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:20 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:15 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:00 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 1:00 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 12:50 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 12:30 PM | 2 days ago |
| SMA: Bearish | Oct 29, 11:20 AM | 2 days ago |
| SMA: Bullish | Oct 29, 11:15 AM | 2 days ago |
| SMA: Bullish | Oct 29, 11:15 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:50 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:50 AM | 2 days ago |
| SMA: Bullish | Oct 29, 10:30 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:25 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 10:15 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:10 AM | 2 days ago |
| SMA: Bullish | Oct 29, 9:35 AM | 2 days ago |
| SMA: Bullish | Oct 29, 9:35 AM | 2 days ago |
| SMA: Bearish | Oct 29, 9:30 AM | 2 days ago |
| SMA: Bearish | Oct 29, 9:30 AM | 2 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:30 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:15 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:00 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:55 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:55 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:10 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 1:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 1:50 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:30 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:25 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:20 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 1:15 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:10 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:30 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 12:30 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 12:25 PM | 3 days ago |
| SMA: Bearish | Oct 28, 11:55 AM | 3 days ago |
| SMA: Bullish | Oct 28, 11:25 AM | 3 days ago |
| SMA: Bullish | Oct 28, 10:50 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 10:50 AM | 3 days ago |
| SMA: Bearish | Oct 28, 10:30 AM | 3 days ago |
| SMA: Bullish | Oct 28, 10:25 AM | 3 days ago |
| RSI: Oversold | Oct 28, 9:50 AM | 3 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 3 days ago |
| RSI: Oversold | Oct 28, 9:30 AM | 3 days ago |
| MACD: Buy Signal | Oct 27, 3:40 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:05 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 3:05 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:00 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:05 PM | 4 days ago |
| SMA: Bearish | Oct 27, 2:00 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 1:30 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:25 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 12:40 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:35 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:25 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:20 PM | 4 days ago |
| SMA: Bullish | Oct 27, 11:35 AM | 4 days ago |
| SMA: Bullish | Oct 27, 11:35 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 11:35 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 11:30 AM | 4 days ago |
| SMA: Bearish | Oct 27, 11:15 AM | 4 days ago |
| SMA: Bearish | Oct 27, 11:05 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:50 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 10:50 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:45 AM | 4 days ago |
| SMA: Bearish | Oct 27, 9:55 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 9:55 AM | 4 days ago |
| RSI: Overbought | Oct 27, 9:40 AM | 4 days ago |
| RSI: Overbought | Oct 26, 3:40 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:30 PM | 5 days ago |
| RSI: Overbought | Oct 26, 3:30 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:15 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:15 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 3:05 PM | 5 days ago |
| SMA: Bearish | Oct 26, 3:00 PM | 5 days ago |
| SMA: Bearish | Oct 26, 3:00 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 2:30 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:25 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:00 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:50 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 1:40 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:10 PM | 5 days ago |
| SMA: Bullish | Oct 26, 12:25 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 12:25 PM | 5 days ago |
| SMA: Bearish | Oct 26, 10:45 AM | 5 days ago |
News
-
1 day ago benzinga.com
Braveheart Bio Announces Late-breaking Presentation Of 52-Week Extension Data For BHB-1893 In Obstructive HCM At The American Heart Association Scientific Sessions, November 6-9; Will Also Host Webinar
Oral Abstract PresentationTitle: HRS/BHB-1893, a Next-Generation Cardiac Myosin Inhibitor, Improves Indices of Diastolic Function in Non-Obstructive Hypertrophic Cardiomyopathy: Evidence From in…
1 day ago globenewswire.com
Braveheart Bio Announces Upcoming Presentations at the American Heart Association Scientific Sessions 2026
SAN FRANCISCO, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic…
1 day ago globenewswire.com
Braveheart Bio to Host Webinar – HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor – with Key Opinion Leader Discussion on November 6, 2026
SAN FRANCISCO, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic…
1 week ago seekingalpha.com
Braveheart Bio: In Non-Obstructive HCM, The Therapeutic Window Is The Product
Braveheart Bio is undervalued as a late-stage HCM player, with two Phase 3 programs fully funded and a differentiated molecule for non-obstructive HCM. BRVE holds $527M in pro forma cash, supporting…
-
1 week ago benzinga.com
Cantor Fitzgerald Reiterates Overweight on Braveheart Bio, Maintains $40 Price Target
Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates Braveheart Bio (NASDAQ:BRVE) with a Overweight and maintains $40 price target.
4 weeks ago defenseworld.net
Braveheart Bio (NASDAQ:BRVE) Stock Falls 7.3% – Here’s What Happened
Shares of Braveheart Bio, Inc. (NASDAQ: BRVE - Get Free Report) were down 7.3% during mid-day trading on Wednesday. The stock traded as low as $20.86 and last traded at $20.7090. 36,478 shares were…
1 month ago globenewswire.com
Braveheart Bio to Participate in Stifel Cardiometabolic Forum
SAN FRANCISCO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic…
-
1 month ago benzinga.com
Braveheart Bio Q2 EPS $(2.51)
Braveheart Bio (NASDAQ:BRVE) reported quarterly losses of $(2.51) per share which missed the analyst consensus estimate of $0.74 by 439.19 percent. This is a 1692.86 percent decrease over losses of…
1 month ago globenewswire.com
Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Phase 3 LIONHEART-HCM Trial of BHB-1893 in Obstructive Hypertrophic Cardiomyopathy (oHCM) Initiated Cash and Cash Equivalents of $122.8 Million as of June 30, 2026, or $527.3 Million After Giving…
2 months ago globenewswire.com
Braveheart Bio to Participate in Cantor Global Healthcare Conference
SAN FRANCISCO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic…
2 months ago benzinga.com
This Airbnb Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
-
2 months ago benzinga.com
Goldman Sachs Initiates Coverage On Braveheart Bio with Buy Rating, Announces Price Target of $48
Goldman Sachs analyst Salveen Richter initiates coverage on Braveheart Bio (NASDAQ:BRVE) with a Buy rating and announces Price Target of $48.
2 months ago benzinga.com
This Lumentum Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
-
2 months ago benzinga.com
Cantor Fitzgerald Initiates Coverage On Braveheart Bio with Overweight Rating, Announces Price Target of $40
Cantor Fitzgerald analyst Olivia Brayer Saunders initiates coverage on Braveheart Bio (NASDAQ:BRVE) with a Overweight rating and announces Price Target of $40.
-
2 months ago benzinga.com
Stifel Initiates Coverage On Braveheart Bio with Buy Rating, Announces Price Target of $45
Stifel analyst James Condulis initiates coverage on Braveheart Bio (NASDAQ:BRVE) with a Buy rating and announces Price Target of $45.
2 months ago fool.com
Braveheart Bio CFO Acquires 27,777 Shares for $500,000. Is This a Signal BRVE IPO Is a Success?
The transaction involved 27,777 shares acquired for ~$500,000 on August 7, 2026. The acquisition increased the total equity position by 5%, resulting in a 0.87% ownership stake.
2 months ago fool.com
Braveheart Bio Chairman Chris Viehbacher Buys $1.5M Shares at IPO. What Does This Mean for Investors?
The transaction involved 83,333 shares with an estimated value of ~$1.5 million as of the August 7, 2026 market close. Director Viehbacher increased his direct equity holdings by 16% through this…
2 months ago fool.com
Braveheart Bio CEO Travis Murdoch Buys 83,333 Shares for $1.5 Million. Is This a Buy Signal for Investors?
Murdoch exercised options at $18 per share, increasing his total beneficial ownership to ~8 million shares valued at $161 million, representing a 13% stake.
2 months ago defenseworld.net
Braveheart Bio (NASDAQ:BRVE) Director Purchases $999,990.00 in Stock
Braveheart Bio, Inc. (NASDAQ: BRVE - Get Free Report) Director David Charles Lubner purchased 55,555 shares of the stock in a transaction dated Friday, August 7th. The shares were acquired at an…
2 months ago defenseworld.net
Braveheart Bio (NASDAQ:BRVE) CFO Buys $499,986.00 in Stock
Braveheart Bio, Inc. (NASDAQ: BRVE - Get Free Report) CFO James Paul Rickey bought 27,777 shares of the company's stock in a transaction on Friday, August 7th. The stock was purchased at an average…
2 months ago globenewswire.com
Braveheart Bio Announces Closing of Upsized Initial Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN FRANCISCO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic…
2 months ago globenewswire.com
Braveheart Bio Announces Pricing of Upsized Initial Public Offering
SAN FRANCISCO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic…
3 months ago seekingalpha.com
Braveheart Bio Readies $300 Million IPO Plan
Braveheart Bio is targeting a $300 million IPO to advance BHB-1893, a promising HCM treatment. BRVE's candidate showed an 86% complete response rate in Phase 2 Chinese trials; Phase 3 trials are…